The history of Viagra and its parent , copyright, presents a complex picture for cautious investors. While the blockbuster drug initially generated enormous earnings, its patent has ended, leading to competing alternatives flooding the landscape . This decline in cost presents a significant obstacle for copyright and any fund considering a signific